{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 405853279
| IUPAC_name = Disodium 4-[(''Z'')-(''tert''-butyl-oxidoazaniumylidene)methyl]benzene-1,3-disulfonate
| image = Disufenton sodium.png

<!--Clinical data-->
| tradename =  
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category =  
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_CA = <!--             / Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL         / P       / POM / CD / Class A, B, C -->
| legal_US = <!-- OTC                   / Rx-only  / Schedule I, II, III, IV, V -->
| legal_status =  
| routes_of_administration =

<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =

<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number =  
| ATC_prefix = none
| ATC_suffix =  
| PubChem = 6440181
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 1627056
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =  
| UNII_Ref = {{fdacite|changed|FDA}}
| UNII = 7M1J3HN9VO
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D03875
|  ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = 28530805

<!--Chemical data-->
| C=11 | H=13 | N=1 | Na=2 | O=7 | S=2 
| molecular_weight = 381.33 g/mol
|  smiles = CC(C)(C)[N+]([O-])=Cc1ccc(cc1S(=O)(=O)[O-])S(=O)(=O)[O-].[Na+].[Na+]
|  StdInChI_Ref = {{stdinchicite|changed|chemspider}}
| StdInChI = 1S/C11H15NO7S2.2Na/c1-11(2,3)12(13)7-8-4-5-9(20(14,15)16)6-10(8)21(17,18)19;;/h4-7H,1-3H3,(H,14,15,16)(H,17,18,19);;/q;2*+1/p-2
|  StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
| StdInChIKey = XLZOVRYBVCMCGL-UHFFFAOYSA-L

}}

'''Disufenton sodium''' ('''NXY-059''', '''Cerovive''') is the disulfonyl derivative of the neuroprotective [[Spin trapping|spin trap]] [[phenylbutylnitrone]] or "PBN".  It was under development at the drug company [[AstraZeneca]].  A 2005 phase-3 clinical trial<ref name="DoiNEJMoa">{{cite journal | doi = 10.1056/NEJMoa052980 | title = NXY-059 for Acute Ischemic Stroke | year = 2006 | last1 = Lees | first1 = Kennedy R. | last2 = Zivin | first2 = Justin A. | last3 = Ashwood | first3 = Tim | last4 = Davalos | first4 = Antonio | last5 = Davis | first5 = Stephen M. | last6 = Diener | first6 = Hans-Christoph | last7 = Grotta | first7 = James | last8 = Lyden | first8 = Patrick | last9 = Shuaib | first9 = Ashfaq| displayauthors = 8 | journal = New England Journal of Medicine | volume = 354 | issue = 6 | pages = 588–600 | pmid = 16467546}}</ref><ref>{{cite journal | pmid = 17068304 | year = 2006 | last1 = Lees | first1 = KR | last2 = Davalos | first2 = A | last3 = Davis | first3 = SM | last4 = Diener | first4 = HC | last5 = Grotta | first5 = J | last6 = Lyden | first6 = P | last7 = Shuaib | first7 = A | last8 = Ashwood | first8 = T | last9 = Hardemark | first9 = HG | displayauthors = 8| title = Additional outcomes and subgroup analyses of NXY-059 for acute ischemic stroke in the SAINT I trial | volume = 37 | issue = 12 | pages = 2970–8 | doi = 10.1161/01.STR.0000249410.91473.44 | journal = Stroke; a journal of cerebral circulation}}</ref> called "SAINT-1" reported some efficacy in the acute treatment of [[ischemia]] injury due to [[stroke]].  However, a 2006 attempt to repeat this trial indicated no significant activity.  After ruling out other causes, the authors tentatively attributed the positive results in the first trial to "chance".<ref name="DoiNEJMoa" /> AstraZeneca then terminated the development programme.<ref>[http://investors.renovis.com/phoenix.zhtml?c=148297&p=irol-newsArticle&t=Regular&id=921678& Renovis: Press Release<!-- Bot generated title -->] {{webarchive |url=https://web.archive.org/web/20061028094321/http://investors.renovis.com/phoenix.zhtml?c=148297&p=irol-newsArticle&t=Regular&id=921678& |date=October 28, 2006 }}</ref>  PBN and its derivatives hydrolyze and oxidize ''in vitro'' to form respectively MNP-OH (AKA, NtBHA) and its parent spin-trap MNP.

==References==
{{reflist}}

==External links==
* [http://jeb.biologists.org/cgi/content/full/207/18/3221 Oxidants, antioxidants and the ischemic brain]
* [http://www.theannals.com/cgi/content/abstract/40/3/461 NXY-059: Review of Neuroprotective Potential for Acute Stroke]

{{AstraZeneca}}

{{DEFAULTSORT:Disufenton Sodium}}
[[Category:Free radicals]]
[[Category:AstraZeneca]]
[[Category:Tert-butyl compounds]]
[[Category:Benzenesulfonates]]
[[Category:Organic sodium salts]]